BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Session Board//Session Board//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:169422-20261203T100000Z@mjbizconference.com
DTSTAMP:20260627T022553Z
DTSTART:20261203T100000Z
DTEND:20261203T104000Z
SUMMARY:Precision Medicine and AI: Engineering the Next Era of Cannabis and Psychedelics Therapeutics
DESCRIPTION:Cannabis and psychedelic therapeutics sit at a scientific inflection point. Clinical evidence is mounting for cannabinoids and compounds like psilocybin and MDMA across pain\, treatment-resistant depression\, PTSD\, and neurological conditions. Yet the field still struggles with a core problem: variability. Patient responses differ widely based on genetics\, metabolism\, the endocannabinoid system\, and complex entourage effects\, making standardized dosing and reproducible outcomes difficult to achieve. \n\n\nPrecision medicine and artificial intelligence offer a path forward. Machine learning models can analyze pharmacogenomic data\, real-world evidence\, and multi-omic datasets to predict individual responses\, refine dosing protocols\, and stratify patients for trials. AI-driven phenotyping and biomarker discovery accelerate the move from anecdotal use toward defensible\, evidence-based therapeutics. \n\n\nThis session unpacks the clinical and technological synergy reshaping the space. The panelists will examine algorithmic dosing models\, predictive analytics in trial design\, and the data infrastructure required to scale responsibly under evolving cannabis business compliance standards. Throughout\, they’ll connect the science to current cannabis market trends and the commercial signals driving investment. 
LOCATION:Breakout Session Room 4 - N115
END:VEVENT
END:VCALENDAR